### Virotherapy Studies performed by Gene- & Virotherapy Center Tübingen (GVCT)

<table>
<thead>
<tr>
<th>Acronym</th>
<th>Sponsor</th>
<th>Study Title</th>
<th>EudraCT</th>
<th>Clinicaltrials.gov</th>
<th>Compounds</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>GL-ONC1</td>
<td>Genelux</td>
<td>Phase I/II study of intraperitoneal administration of GL-ONC1, a genetically modified vaccinia virus, in patients with peritoneal carcinomatosis</td>
<td>2010-022680-35</td>
<td>NCT01443260</td>
<td>Virotherapy</td>
<td>Peritoneal Carcinomatosis</td>
</tr>
<tr>
<td>AMG 299</td>
<td>AMGEN</td>
<td>Phase Ib study of Talimogene Laherparepvec combined with Atezolizumab in subjects with TNBC and CRC</td>
<td>2015-005480-16</td>
<td>NCT03256344</td>
<td>Virotherapy</td>
<td>Herpes-Simplex Virus</td>
</tr>
<tr>
<td>AMG 318</td>
<td>AMGEN</td>
<td>Phase Ib/II, multicenter, open-label study to evaluate the safety of Talimogene Laherparepvec injected into liver tumors alone and in combination with systemic Pembrolizumab</td>
<td>2014-005386-67</td>
<td>NCT02509507</td>
<td>Virotherapy</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>AMG 115</td>
<td>AMGEN</td>
<td>Phase II study of Talimogene Laherparepvec in combination with Pembrolizumab in subjects with unresectable/metastatic stage IIIIB-IVM1c Melanoma who have progressed on prior anti-PT-1 based therapy</td>
<td>2019-001906-61</td>
<td>NCT04068181</td>
<td>Virotherapy</td>
<td>Herpes-Simplex Virus</td>
</tr>
<tr>
<td>BI1456-0001</td>
<td>BI</td>
<td>Phase I open-label, dose escalation study of BI 1831169 monotherapy and in combination with BI 754091 in patients with advanced or metastatic solid tumors</td>
<td>2020-003902-30</td>
<td>NCT05155332</td>
<td>Virotherapy</td>
<td>Vesicular Stomatitis Virus</td>
</tr>
<tr>
<td>V937-013</td>
<td>MSD</td>
<td>Phase Ib/II study of intratumoral administration of V937 in combination with Pembrolizumab in participants with advanced/metastatic solid tumors</td>
<td>2020-001908-42</td>
<td>NCT04521621</td>
<td>Virotherapy</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>V937-011</td>
<td>MSD</td>
<td>A Phase II, study of i.v. or Intratumoral administration of V937 in combination with Pembrolizumab versus Pembrolizumab alone in participants with advanced/metastatic melanoma</td>
<td>2019-002034-36</td>
<td>NCT04152863</td>
<td>Virotherapy</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>GOBLET</td>
<td>ONCOLYTICS BIOTECH</td>
<td>Phase I/II multiple-indication biomarker, safety, and efficacy study in advanced or metastatic GI cancers exploring treatment combinations with Peleareop and Atezolizumab</td>
<td>2020-003996-16</td>
<td>N.N.</td>
<td>Virotherapy</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>TMV-018</td>
<td>UKT</td>
<td>Phase I/II open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intratumoral application of TMV-018 in combination with 5-Fluorocytosine or anti-PD-1 therapy in GI tumors</td>
<td>2019-003550-88</td>
<td>NCT04195373</td>
<td>Virotherapy</td>
<td>Measles Vaccine Virus</td>
</tr>
<tr>
<td>TMV-018</td>
<td>UKT</td>
<td>A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic-Dynamic and Clinical Activity Study of intratumoral application of virotherapeutic compound TMV-018 plus i.v. application of the prodrug 5-Fluorocytosine in combination with Pembrolizumab in patients with injectable solid tumors</td>
<td>N.N.</td>
<td>N.N.</td>
<td>Virotherapy</td>
<td>Measles Vaccine Virus</td>
</tr>
<tr>
<td>RADNET</td>
<td>UKT</td>
<td>Phase I/IIa study of recombinant adenovirus AdVince in patients with neuroendocrine neoplasms</td>
<td>2014-000614-64</td>
<td>NCT02749331</td>
<td>Virotherapy</td>
<td>Adenovirus</td>
</tr>
<tr>
<td>VALO-001</td>
<td>VALO</td>
<td>A Phase I, open-label, non-randomized study to evaluate the safety and immune activity of PeptiCRAd-1, a tumor-specific peptide coated conditionally replicating adenovirus, in combination with immune checkpoint inhibitor pembrolizumab in patients with injectable solid tumors in indications known to express NY-ESO-1 and MAGE-A3</td>
<td>2021-002529-13</td>
<td>N.N.</td>
<td>Virotherapy</td>
<td>Measles Vaccine Virus</td>
</tr>
</tbody>
</table>

**Sponsor**

- AMGEN
- Genelux
- BI
- MSD
- ONCOLYTICS BIOTECH
- UKT
- VALO

**Study Title**

- Phase III study of intraperitoneal administration of GL-ONC1, a genetically modified vaccinia virus, in patients with peritoneal carcinomatosis
- A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / TK-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced HCC Without Prior Systemic Therapy
- Phase Ib study of Talimogene Laherparepvec combined with Atezolizumab in subjects with TNBC and CRC
- Phase Ib/II, multicenter, open-label study to evaluate the safety of Talimogene Laherparepvec injected into liver tumors alone and in combination with systemic Pembrolizumab
- Phase II study of Talimogene Laherparepvec in combination with Pembrolizumab in subjects with unresectable/metastatic stage IIIIB-IVM1c Melanoma who have progressed on prior anti-PT-1 based therapy
- Phase I open-label, dose escalation study of BI 1831169 monotherapy and in combination with BI 754091 in patients with advanced or metastatic solid tumors
- Phase Ib/II study of intratumoral administration of V937 in combination with Pembrolizumab in participants with advanced/metastatic solid tumors
- Phase Ib/II study of intratumoral administration of V937 in combination with Pembrolizumab versus Pembrolizumab alone in participants with advanced/metastatic melanoma
- Phase I/II multiple-indication biomarker, safety, and efficacy study in advanced or metastatic GI cancers exploring treatment combinations with Peleareop and Atezolizumab
- Phase I/II open-label, dose-escalation, safety, clinical activity, pharmacokinetic and pharmacodynamic study of intratumoral application of TMV-018 in combination with 5-Fluorocytosine or anti-PD-1 therapy in GI tumors
- A Phase I, Open-label, Dose-escalation, Safety, Pharmacokinetic-Dynamic and Clinical Activity Study of intratumoral application of virotherapeutic compound TMV-018 plus i.v. application of the prodrug 5-Fluorocytosine in combination with Pembrolizumab in patients with injectable solid tumors
- Phase I/IIa study of recombinant adenovirus AdVince in patients with neuroendocrine neoplasms
- A Phase I, open-label, non-randomized study to evaluate the safety and immune activity of PeptiCRAd-1, a tumor-specific peptide coated conditionally replicating adenovirus, in combination with immune checkpoint inhibitor pembrolizumab in patients with injectable solid tumors in indications known to express NY-ESO-1 and MAGE-A3

**Compounds**

- Virotherapy
- Vaccinia Virus
- Herpes-Simplex Virus
- Solid Tumors
- Melanoma
- Solid Tumors
- Reovirus
- Measles Vaccine Virus
- Solid Tumors
- Adenovirus
- Measles Vaccine Virus
- Solid Tumors
- Measles Vaccine Virus
- Solid Tumors
- Melanoma
- Solid Tumors
- Adenovirus